REGN
Regeneron Pharmaceuticals, Inc.Company with tickers: REGN
CIK
872589
CUSIP
75886F107
Shares Outstanding
103,021,886
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $3,605,400,000 | USD | 2026-03-31 | 10-Q | 2026-04-29 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | $1,543,500,000 | USD | 2026-03-31 | 10-Q | 2026-04-29 |
| Operating Income | $642,900,000 | USD | 2026-03-31 | 10-Q | 2026-04-29 |
| Net Income | $727,200,000 | USD | 2026-03-31 | 10-Q | 2026-04-29 |
| EPS (Basic) | $6.99 | USD/shares | 2026-03-31 | 10-Q | 2026-04-29 |
| EPS (Diluted) | $6.75 | USD/shares | 2026-03-31 | 10-Q | 2026-04-29 |